Comparative Pharmacology
Head-to-head clinical analysis: FERRIC CITRATE versus SEVELAMER CARBONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERRIC CITRATE versus SEVELAMER CARBONATE.
FERRIC CITRATE vs SEVELAMER CARBONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ferric citrate dissociates to provide ferric iron, which binds dietary phosphate in the gastrointestinal tract, forming insoluble ferric phosphate that is excreted in feces, thereby reducing serum phosphate levels. It also provides iron for erythropoiesis.
Sevelamer carbonate is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, thereby reducing phosphate absorption and serum phosphate levels. It also binds bile acids and may reduce LDL cholesterol.
1-2 tablets (210-420 mg elemental iron) orally three times daily with meals.
Adults: 800 to 1600 mg orally three times daily with meals, titrated according to serum phosphorus targets.
None Documented
None Documented
Approximately 6 hours for absorbed iron; clinical effect on serum phosphate occurs within 1–2 weeks.
Not applicable. Sevelamer carbonate is not systemically absorbed and thus has no measurable plasma half-life. Its pharmacological effect correlates with gastrointestinal transit time, which is typically 24-48 hours.
Primarily fecal as unabsorbed iron (≥90%); minimal renal excretion (<1%) of absorbed iron.
Sevelamer carbonate is not absorbed systemically; it acts locally in the gastrointestinal tract. Excretion is entirely fecal, with no renal or biliary elimination. The polymer is excreted unchanged in the feces.
Category C
Category A/B
Phosphate Binder
Phosphate Binder